Evidence map›Paper›PMID 31804810›Full record

ReviewChemical reviews2020

Peptide-Based Vaccines: Current Progress and Future Challenges.

Ryan J Malonis, Jonathan R Lai, Olivia Vergnolle

Open access · greenAbstract readReview
In one paragraph

Review in Chemical reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 311 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
311citing papers in PubMed, 1 pooled it
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

311 citing papers in PubMed, 1 synthesis or guideline pooled it, 594 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

251 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryan J MalonisDepartment of Biochemistry, Albert Einstein College of Medicine, Michael F. Price Center for Translational Research, 1301 Morris Park Avenue, Bronx, New York 10461, United States.
Jonathan R LaiDepartment of Biochemistry, Albert Einstein College of Medicine, Michael F. Price Center for Translational Research, 1301 Morris Park Avenue, Bronx, New York 10461, United States.ORCID 0000-0002-4863-0015
Olivia VergnolleDepartment of Biochemistry, Albert Einstein College of Medicine, Michael F. Price Center for Translational Research, 1301 Morris Park Avenue, Bronx, New York 10461, United States.
Albert Einstein College of Medicine · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007288 · NIGMS · YESHIVA UNIVERSITY · PI AKABAS, MYLES H. · 1985 to 2022
$35.6M
A "Trojan Horse" bispecific antibody strategy for broad filovirus therapeuticsR01AI132256 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI CHANDRAN, KARTIK, LAI, JONATHAN R. · 2017 to 2021
$6.1M
Engineered, multispecific antibodies as broad anti-filovirus therapeuticsR01AI125462 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI LAI, JONATHAN R. · 2017 to 2020
$3.0M
Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus DiseaseR42AI122403 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, LAI, JONATHAN R. · 2017 to 2018
$1.9M
NIAID NIH HHS R01 AI125462NIAID NIH HHS R01 AI132256NIAID NIH HHS R42 AI122403NIGMS NIH HHS T32 GM007288
6 · The paper itself

Abstract

Vaccines have had a profound impact on the management and prevention of infectious disease. In addition, the development of vaccines against chronic diseases has attracted considerable interest as an approach to prevent, rather than treat, conditions such as cancer, Alzheimer's disease, and others. Subunit vaccines consist of nongenetic components of the infectious agent or disease-related epitope. In this Review, we discuss peptide-based vaccines and their potential in three therapeutic areas: infectious disease, Alzheimer's disease, and cancer. We discuss factors that contribute to vaccine efficacy and how these parameters may potentially be modulated by design. We examine both clinically tested vaccines as well as nascent approaches and explore current challenges and potential remedies. While peptide vaccines hold substantial promise in the prevention of human disease, many obstacles remain that have hampered their clinical use; thus, continued research efforts to address these challenges are warranted.

Indexed as

Vaccines, SubunitAlzheimer DiseaseAnimalsHumansInfection ControlNeoplasmsVaccines, Subunit

Identifiers

PMID31804810
PMCPMC7094793
OpenAlexW2992070886

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.